Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Olschewski, H.
[Pulmonary embolism and direct oral anticoagulants].
WIEN MED WOCHENSCHR. 2018; 168(5-6): 144-147. Doi: 10.1007/s10354-016-0449-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Olschewski Horst
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: A new European guideline for the diagnostics and therapy of venous thromboembolism has been published in 2014. As previously, high-risk and low-risk pulmonary embolism is distinguished, however, in the new guideline there is also a definition of intermediate risk PE. The risk finally decides about the diagnostic and therapeutic procedure.Previously, nearly only heparinoids were available for therapy of acute venous thromboembolism and after some days they were switched to a vitamin K antagonist. The direct oral anticoagulants (DOAC) represent a group of drugs that start working as rapidly as heparinoids and can be applied as long-term oral medication. In contrast to vitamin K antagonists, repeated coagulation tests are not necessary. Dosing is easy, although in quite a few cases dose adaptations compared to the standard dose may be necessary. The following article tries to give a rapid orientation.
Find related publications in this database (Keywords): Pulmonary embolism; Anticoagulation; Thrombolysis; Direct oral anticoagulants